Biliary Atresia Therapeutics Market Report 2026

Biliary Atresia Therapeutics Market Overview

• Biliary Atresia Therapeutics market size has reached to $1.02 billion in 2025 • Expected to grow to $1.53 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Expansion Of Neonatal Screening Programs Driving The Market Growth Due To Increasing Early Detection And Timely Diagnosis Of Congenital Disorders • Market Trend: Clinical Trial Achieves Key Milestone In Evaluation Of Oral Therapy For Pediatric Liver Disease • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biliary Atresia Therapeutics Market?

Biliary atresia therapeutics refer to pharmaceutical and medical treatment approaches used to manage biliary atresia, a rare liver disorder characterized by blockage or absence of bile ducts. These therapeutics are designed to improve bile flow, reduce liver damage, manage complications, and support liver function. The main treatment types of biliary atresia therapeutics include surgical procedures, medication, liver transplantation, and other treatment types. Surgical procedures refer to interventions such as the Kasai portoenterostomy that help restore bile flow and improve liver function in patients with biliary atresia. These therapies are used across age groups including neonates, infants, and pediatric patients. They are administered through oral, injectable, and other routes of administration and they are utilized by end users including hospitals, specialty clinics, ambulatory surgical centers, and others.

What Is The Biliary Atresia Therapeutics Market Growth Forecast?

The biliary atresia therapeutics market size is expected to see strongly grown in the next few years. It will grow to $1.53 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to development of novel bile flow enhancing therapies, increasing adoption of personalized treatment approaches, expansion of pediatric specialty care infrastructure, rising investment in rare disease therapeutics, growth in advanced surgical intervention capabilities. Major trends in the forecast period include advancements in minimally invasive biliary surgery techniques, increasing adoption of early diagnosis and intervention programs, growing use of combination medication therapies for liver function support, expansion of pediatric liver transplantation programs, rising focus on post operative care and long term disease management.

Global Biliary Atresia Therapeutics Market Segmentation

1) By Treatment Type: Surgical Procedures; Medication; Liver Transplantation; Other Treatment Types 2) By Age Group: Neonates; Infants; Pediatric Patients 3) By Route Of Administration: Oral; Injectable; Other Route Of Administrations 4) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End Users Subsegments: 1) By Surgical Procedures: Kasai Portoenterostomy; Minimally Invasive Biliary Surgery; Robotic Assisted Biliary Surgery; Revision Surgical Procedures 2) By Medication: Corticosteroid Therapy; Antibiotic Therapy; Immunosuppressive Therapy; Bile Acid Therapy; Nutritional Supplement Therapy 3) By Liver Transplantation: Living Donor Liver Transplantation; Deceased Donor Liver Transplantation; Split Liver Transplantation; Pediatric Liver Retransplantation 4) By Other Treatment Types: Supportive Nutritional Care; Post Operative Care Management; Pediatric Hepatology Monitoring; Palliative Care Services

What Is The Driver Of The Biliary Atresia Therapeutics Market?

The expansion of neonatal screening programs is expected to propel the growth of the biliary atresia therapeutics market going forward. Neonatal screening programs refer to systematic public health initiatives that test newborns shortly after birth to detect congenital, genetic, and metabolic disorders at an early stage. Neonatal screening programs are growing due to increasing government initiatives and healthcare policies focused on early detection and timely treatment of congenital and genetic disorders in newborns. Expansion of neonatal screening programs enables earlier identification of affected newborns, allowing timely medical intervention and increasing the need for effective treatment approaches to manage disease progression and improve clinical outcomes. For instance, in March 2026, according to touchENDOCRINOLOGY, a UK-based peer-reviewed journal, the UK National Screening Committee (UK NSC) launched a consultation on newborn screening for biliary atresia, a rare liver disease affecting about 1 in 17,000 babies in the UK, where early detection is critical as treatment within the first 2 months significantly improves outcomes, though uncertainty remains about the effectiveness of population-wide screening. Therefore, the expansion of neonatal screening programs is driving the growth of the biliary atresia therapeutics industry.

Key Players In The Global Biliary Atresia Therapeutics Market

Major companies operating in the biliary atresia therapeutics market are Ipsen S.A.; Mirum Pharmaceuticals Inc.; CANbridge Pharmaceuticals Inc.

Global Biliary Atresia Therapeutics Market Trends and Insights

Major companies operating in the biliary atresia therapeutics market are focusing on advancing clinical trials to develop innovative treatment options, such as ileal bile acid transporter (IBAT) inhibitor-based therapies to improve bile flow, reduce liver damage, and delay or prevent the need for liver transplantation in pediatric patients. IBAT inhibitor-based therapies refer to oral small-molecule drugs that work by blocking bile acid reabsorption in the intestine, thereby reducing toxic bile acid buildup in the liver, improving liver function, and supporting better clinical outcomes in cholestatic liver diseases such as biliary atresia. For instance, in May 2023, Mirum Pharmaceuticals, a US-based biopharmaceutical company, announced the completion of enrollment in its Phase 2b EMBARK study evaluating LIVMARLI (maralixibat) oral solution for pediatric patients with biliary atresia. The study is a global, double-blind, randomized, placebo-controlled trial designed to assess the efficacy and safety of the therapy in infants who had previously undergone the Kasai procedure (hepatoportoenterostomy). The EMBARK study represents the first completed randomized clinical trial of an ileal bile acid transporter (IBAT) inhibitor for biliary atresia, with topline results expected in the second half of 2023, and is expected to provide important insights into improving liver function and delaying disease progression in this rare pediatric liver disorder.

What Are Latest Mergers And Acquisitions In The Biliary Atresia Therapeutics Market?

In March 2023, Ipsen S.A., a France-based biopharmaceutical company, acquired Albireo Pharma Inc. for $952 million. With this acquisition, Ipsen S.A. aimed to significantly expand its rare disease franchise, particularly in rare pediatric and cholestatic liver diseases, by adding innovative bile-acid modulation therapies and strengthening its late-stage and commercial pipeline in hepatology. Albireo Pharma Inc. is a US-based biotechnology company that specializes in developing bylvay (odevixibat) as a potential therapeutic for biliary atresia.

Regional Outlook

North America was the largest region in the biliary atresia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biliary Atresia Therapeutics Market?

The biliary atresia therapeutics market consists of sales of corticosteroids, antibiotics, antiviral drugs, bile acid therapies, immunosuppressants, nutritional supplements, liver support medications, and related therapeutic products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, healthcare providers, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biliary Atresia Therapeutics Market Report 2026?

The biliary atresia therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biliary atresia therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.